Mirati Theraps patent expiration

1. Krazati patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10689377 MIRATI THERAPS KRas G12C inhibitors
May, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 12, 2027
Orphan Drug Exclusivity(ODE-352) Dec 12, 2029

Drugs and Companies using ADAGRASIB ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 12 December, 2022

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda approved test, who have received at least one prior system...

Dosage: TABLET

More Information on Dosage

KRAZATI family patents

Family Patents